Italian Prime Minister Mario Draghi recently expressed his doubts that the Russian-made Sputnik V Covid19 vaccine would be granted approval for use in the European Union (EU).
Draghi added that China’s Sinovac vaccine may share the same fate as Sputnik V.
The Prime Minister cited the situation in Chile, which heavily relied on Sinovac to inoculate over 70% of its population with at least one dose, wherein Covid19 cases are on the rise and officials are eyeing a third dose to boost immunization.
This surging number of infections in Chile has cast additional scrutiny on Sinovac’s overall effectiveness against Covid19.
As of writing, both Sputnik V and Sinovac are undergoing a “rolling review” process by the European Medicines Agency (EMA), necessary for obtaining formal approval.
At an EU summit, Draghi spoke of the need for strengthening and reforms within the EMA in order to prevent future vaccine confusions.
He was mentioned recent discrepancies with regard to safety details of Covid19 vaccines between the EMA and national medicine agencies, but did not give specifics.
Meanwhile in the Philippines, both Sinovac and Sputnik V were granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) earlier in the year, and have been utilized in the country’s vaccination program.
As of June 27, 6.93% of the country’s total population has been inoculated with their first vaccine dose, while 2.32% have received both jabs.